PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma (Tri-Med)
Active Ingredients: Trenbolone Acetate (60 mg/ml), Trenbolone Hexahydrobenzylcarbonate (60 mg/ml), Trenbolone Enanthate (60 mg/ml) — Total Strength: 180 mg/ml
Pharmacological Class: Multi-Ester $19\text{-Nortestosterone}$ Derivative / Tri-Ester Trenbolone Blend
Tri-Med 180 mg/ml by Bioniche Pharma is a specialized triple-ester injectable formulation incorporating short (acetate), intermediate (hexahydrobenzylcarbonate), and long-acting (enanthate) esters of Trenbolone. Engineered by Bioniche Pharma to achieve both an immediate systemic response and prolonged blood plasma hormone concentrations, Tri-Med enhances protein metabolism, maintains a strongly positive nitrogen balance, suppresses catabolic activity, and supports rapid skeletal muscle recovery and growth when backed by adequate nutritional intake.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
The tri-ester matrix combines distinct pharmacokinetic profiles: Trenbolone Acetate delivers a rapid initial surge in plasma levels, while Trenbolone Hexahydrobenzylcarbonate and Trenbolone Enanthate release at slower, staggered rates to sustain therapeutic androgen concentrations. Upon binding to intracellular androgen receptors, Trenbolone drives cellular protein synthesis, enhances nitrogen retention, and increases IGF-1 expression within muscle tissue. As a non-aromatizing $19\text{-nor}$ derivative, it exerts potent anabolic effects without converting directly into estradiol.
INDICATIONS & CLINICAL USE
- Anabolic therapy for promoting nitrogen retention, protein anabolism, and accelerated tissue regeneration.
- Reversal of catabolic muscle wasting and support of lean body mass accretion in debilitated states under medical supervision.
CONTRAINDICATIONS
- Male patients with known, suspected, or treated carcinoma of the prostate gland or male breast cancer.
- Female patients with breast carcinoma complicated by hypercalcemia (elevated serum calcium levels).
- Females who are pregnant or may become pregnant due to extreme risks of fetal virilization, malformation, and severe endocrine toxicity. Women must strictly avoid this product under all circumstances.
- Patients with severe cardiac failure, advanced hepatic disease, or severe renal impairment.
- Patients with documented hypersensitivity or allergic reaction to any of the Trenbolone esters, carrier oils, or inactive components in Bioniche Pharma Tri-Med.
ADVERSE REACTIONS & SPECIAL PRECAUTIONS
- Dermatological & Androgenic: Severe acne vulgaris (commonly appearing on the face, shoulders, upper and lower arms, chest, and back during early therapy), oily skin, and accelerated hair loss (androgenetic alopecia).
- Behavioral & CNS: Dose-dependent increases in aggressive behavior, mood alterations, irritability, and sleep disturbances, particularly at elevated doses.
- Systemic & Organ Monitoring: Continuous clinical surveillance of renal function, hepatic transaminases, blood pressure, and serum lipid fractions is strongly indicated during therapy.
- Endocrine Suppression: Severe and rapid suppression of the endogenous Hypothalamic-Pituitary-Testicular Axis (HPTA), leading to secondary hypogonadism and testicular atrophy.
DOSAGE & ADMINISTRATION
Bioniche Pharma Tri-Med is formulated strictly for deep intramuscular injection. Because of the inclusion of the fast-acting acetate ester alongside long-acting esters, administration timing must be precisely maintained to avoid hormone fluctuations:
- Prescribed Dosage: The most common clinical dosage is 180 mg (1 ml) injected every other day intramuscularly, or as titrated and adjusted according to medical advice and individual patient tolerance.
- Restricted Populations: Strictly contraindicated for use in women, pediatric patients, and adolescents.
STORAGE & HANDLING
Store Bioniche Pharma injectable products in a cool, dry place protected from direct light exposure and excess heat. Do not refrigerate or freeze. Keep strictly out of reach and sight of children.